A late-stage drug development company specialized in endocrine and oncology therapy.

Only one patient had a dosage reduction, and overall, 25 of 170 classes were given with a delay, including also full cases in which delay was not linked to toxicity. Severe toxicity was primarily restricted to quickly reversible hematologic toxicity connected with fever in 3 cases. Great tolerability of AEZS-108 was also reflected with only a few sufferers with non-hematological toxicities of quality 3 , including single cases each of nausea, constipation, poor general condition, and an enzyme elevation. No cardiac toxicity was reported. The efficacy of AEZS-108 inside our research was encouraging, considering that it only included patients resistant to prior platinum – and taxane-centered therapies , commented Prof. In these individuals, a clinical benefit rate of 38 percent and particularly a median overall survival of over 15 months compare favourably with results for drugs such as topotecan and pegylated liposomal doxorubicin that are currently used in this setting.For this, we plan to conduct a scientific trial, before year result in Germany, on one or even more formulations of insulin analog.

A new breakthrough for treating nasopharyngeal carcinoma A group of scientists from the Cancers Research Institute of Singapore at the National University of Singapore, National University Cancers Institute Singapore and National University Medical center Singapore , discovered a distinct mutational signature and nine mutated genes associated with nasopharyngeal cancer significantly, paving the real method to developing novel therapies for this deadly disease.